{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:52:08Z","timestamp":1758124328795,"version":"3.38.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1038\/bjc.2011.275","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T22:56:12Z","timestamp":1312930572000},"page":"513-522","source":"Crossref","is-referenced-by-count":11,"title":["Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells"],"prefix":"10.1038","volume":"105","author":[{"given":"M B","family":"Lucia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Anu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Handley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-P","family":"Gillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-P","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G M","family":"De Donatis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Cauda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M M","family":"Gottesman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,9]]},"reference":[{"key":"BFbjc2011275_CR1","first-page":"3084","volume":"63","author":"C Aleman","year":"2003","unstructured":"Aleman C, Annereau JP, Liang XJ, Cardarelli CO, Taylor B, Yin JJ, Aszalos A, Gottesman MM (2003) P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 63: 3084\u20133091","journal-title":"Cancer Res"},{"key":"BFbjc2011275_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003088-200544020-00001","volume":"44","author":"T Antoniou","year":"2005","unstructured":"Antoniou T, Tseng AL (2005) Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44: 111\u2013145","journal-title":"Clin Pharmacokinet"},{"key":"BFbjc2011275_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.ajpath.2010.10.029","volume":"178","author":"L Bao","year":"2011","unstructured":"Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetly R, Dash S (2011) Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol 178: 838\u2013852","journal-title":"Am J Pathol"},{"key":"BFbjc2011275_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/COH.0b013e328313915d","volume":"3","author":"WB Bernstein","year":"2008","unstructured":"Bernstein WB, Dennis PA (2008) Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS 3: 666\u2013675","journal-title":"Curr Opin HIV AIDS"},{"key":"BFbjc2011275_CR5","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/jac\/dkq209","volume":"65","author":"WF Bierman","year":"2010","unstructured":"Bierman WF, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, Danner SA, Scheper RJ (2010) Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 65: 1672\u20131680","journal-title":"J Antimicrob Chemother"},{"key":"BFbjc2011275_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrc797","volume":"2","author":"C Boshoff","year":"2002","unstructured":"Boshoff C, Weiss R (2002) AIDS-related malignancies. Nat Rev Cancer 2: 373\u2013382","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2011275_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1468-1293.2008.00608.x","volume":"9","author":"M Bower","year":"2008","unstructured":"Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales N, Webb A (2008) British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 9: 336\u2013388","journal-title":"HIV Med"},{"key":"BFbjc2011275_CR8","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2007.15.2355","volume":"26","author":"TB Brunner","year":"2008","unstructured":"Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG (2008) Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 26: 2699\u20132706","journal-title":"J Clin Oncol"},{"key":"BFbjc2011275_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0091270007311568","volume":"48","author":"R Callaghan","year":"2008","unstructured":"Callaghan R, Crowley E, Potter S, Kerr ID (2008) P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 48: 365\u2013378","journal-title":"J Clin Pharmacol"},{"key":"BFbjc2011275_CR10","doi-asserted-by":"publisher","first-page":"8361","DOI":"10.1158\/0008-5472.CAN-08-0878","volume":"68","author":"R Chaisuparat","year":"2008","unstructured":"Chaisuparat R, Hu J, Jham BC, Knight ZA, Shokat KM, Montaner S (2008) Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res 68: 8361\u20138368","journal-title":"Cancer Res"},{"key":"BFbjc2011275_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(08)70334-6","volume":"10","author":"WA Chow","year":"2009","unstructured":"Chow WA, Jiang C, Guan M (2009) Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 10: 61\u201371","journal-title":"Lancet Oncol"},{"key":"BFbjc2011275_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","volume":"63","author":"RS Cvetkovic","year":"2003","unstructured":"Cvetkovic RS, Goa KL (2003) Lopinavir\/ritonavir: a review of its use in the management of HIV infection. Drugs 63: 769\u2013802","journal-title":"Drugs"},{"key":"BFbjc2011275_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1586\/14737140.5.2.215","volume":"5","author":"T Dhillon","year":"2005","unstructured":"Dhillon T, Stebbing J, Bower M (2005) Paclitaxel for AIDS-associated Kaposi's sarcoma. Expert Rev Anticancer Ther 5: 215\u2013219","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFbjc2011275_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/CCO.0b013e3281eb8ea7","volume":"19","author":"DP Dittmer","year":"2007","unstructured":"Dittmer DP, Krown SE (2007) Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 19: 452\u2013457","journal-title":"Curr Opin Oncol"},{"key":"BFbjc2011275_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1046\/j.1468-1293.2003.00169.x","volume":"4","author":"ML Dupuis","year":"2003","unstructured":"Dupuis ML, Flego M, Molinari A, Cianfriglia M (2003a) Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. HIV Med 4: 338\u2013345","journal-title":"HIV Med"},{"key":"BFbjc2011275_CR16","first-page":"387","volume":"38","author":"ML Dupuis","year":"2002","unstructured":"Dupuis ML, Tombesi M, Cianfriglia M (2002) Modulation of the multidrug resistance (MDR) phenotype in CEM MDR cells simultaneously exposed to anti HIV-1 protease inhibitors (PI's) and cytotoxic drugs. Ann Ist Super Sanita 38: 387\u2013392","journal-title":"Ann Ist Super Sanita"},{"key":"BFbjc2011275_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000069782","volume":"49","author":"ML Dupuis","year":"2003","unstructured":"Dupuis ML, Tombesi M, Sabatini M, Cianfriglia M (2003b) Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. Chemotherapy 49: 8\u201316","journal-title":"Chemotherapy"},{"key":"BFbjc2011275_CR18","doi-asserted-by":"publisher","first-page":"33309","DOI":"10.1074\/jbc.C100375200","volume":"276","author":"I Dussault","year":"2001","unstructured":"Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM (2001) Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 276: 33309\u201333312","journal-title":"J Biol Chem"},{"key":"BFbjc2011275_CR19","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1200\/JCO.2002.12.038","volume":"20","author":"SR Evans","year":"2002","unstructured":"Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH (2002) Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol 20: 3236\u20133241","journal-title":"J Clin Oncol"},{"key":"BFbjc2011275_CR20","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nchembio817","volume":"2","author":"JB Fitzgerald","year":"2006","unstructured":"Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458\u2013466","journal-title":"Nat Chem Biol"},{"key":"BFbjc2011275_CR21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0026-895X(25)09640-3","volume":"36","author":"BM Foxwell","year":"1989","unstructured":"Foxwell BM, Mackie A, Ling V, Ryffel B (1989) Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 36: 543\u2013546","journal-title":"Mol Pharmacol"},{"key":"BFbjc2011275_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.leukres.2008.06.010","volume":"33","author":"MG Garcia","year":"2009","unstructured":"Garcia MG, Alaniz LD, Cordo Russo RI, Alvarez E, Hajos SE (2009) PI3K\/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk Res 33: 288\u2013296","journal-title":"Leuk Res"},{"key":"BFbjc2011275_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48\u201358","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2011275_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2003.09.039","volume":"205","author":"M Granzotto","year":"2004","unstructured":"Granzotto M, Drigo I, Candussio L, Rosati A, Bartoli F, Giraldi T, Decorti G (2004) Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. Cancer Lett 205: 107\u2013115","journal-title":"Cancer Lett"},{"key":"BFbjc2011275_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1593\/neo.07124","volume":"9","author":"AK Gupta","year":"2007","unstructured":"Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A (2007) The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 9: 271\u2013278","journal-title":"Neoplasia"},{"key":"BFbjc2011275_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1023\/A:1027381705962","volume":"18","author":"S Gupta","year":"1998","unstructured":"Gupta S, Aggarwal S, Nakamura S (1998) A possible role of multidrug resistance-associated protein (MRP) in basic fibroblast growth factor secretion by AIDS-associated Kaposi's sarcoma cells: a survival molecule? J Clin Immunol 18: 256\u2013263","journal-title":"J Clin Immunol"},{"key":"BFbjc2011275_CR27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/00002030-199405000-00002","volume":"8","author":"BG Herndier","year":"1994","unstructured":"Herndier BG, Werner A, Arnstein P, Abbey NW, Demartis F, Cohen RL, Shuman MA, Levy JA (1994) Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals. AIDS 8: 575\u2013581","journal-title":"AIDS"},{"key":"BFbjc2011275_CR28","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/S0021-9258(18)53865-5","volume":"268","author":"CE Herzog","year":"1993","unstructured":"Herzog CE, Tsokos M, Bates SE, Fojo AT (1993) Increased mdr-1\/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 268: 2946\u20132952","journal-title":"J Biol Chem"},{"key":"BFbjc2011275_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/bjp.2008.320","volume":"155","author":"O Janneh","year":"2008","unstructured":"Janneh O, Hartkoorn RC, Jones E, Owen A, Ward SA, Davey R, Back DJ, Khoo SH (2008) Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol 155: 875\u2013883","journal-title":"Br J Pharmacol"},{"key":"BFbjc2011275_CR30","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1021\/bi972709x","volume":"37","author":"CG Lee","year":"1998","unstructured":"Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37: 3594\u20133601","journal-title":"Biochemistry"},{"key":"BFbjc2011275_CR31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0026-895X(25)09793-7","volume":"46","author":"JS Lee","year":"1994","unstructured":"Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 46: 627\u2013638","journal-title":"Mol Pharmacol"},{"key":"BFbjc2011275_CR32","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1056\/NEJMc070508","volume":"357","author":"T Maurer","year":"2007","unstructured":"Maurer T, Ponte M, Leslie K (2007) HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 357: 1352\u20131353","journal-title":"N Engl J Med"},{"key":"BFbjc2011275_CR33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/QAD.0b013e3283262a8d","volume":"23","author":"P Monini","year":"2009","unstructured":"Monini P, Sgadari C, Grosso MG, Bellino S, Di Biagio A, Toschi E, Bacigalupo I, Sabbatucci M, Cencioni G, Salvi E, Leone P, Ensoli B (2009) Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 23: 534\u2013538","journal-title":"AIDS"},{"key":"BFbjc2011275_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0378-4347(97)00414-3","volume":"703","author":"C Mou","year":"1997","unstructured":"Mou C, Ganju N, Sridhar KS, Krishan A (1997) Simultaneous quantitation of plasma doxorubicin and prochlorperazine content by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 703: 217\u2013224","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"BFbjc2011275_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.critrevonc.2008.10.013","volume":"72","author":"N Mounier","year":"2009","unstructured":"Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP (2009) Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice. Crit Rev Oncol Hematol 72: 10\u201320","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFbjc2011275_CR36","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/QAD.0b013e3282ff6275","volume":"22","author":"HQ Nguyen","year":"2008","unstructured":"Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, Casper C (2008) Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22: 937\u2013945","journal-title":"AIDS"},{"key":"BFbjc2011275_CR37","doi-asserted-by":"publisher","first-page":"e1000389","DOI":"10.1371\/journal.ppat.1000389","volume":"5","author":"AJ O\u2019Hara","year":"2009","unstructured":"O\u2019Hara AJ, Chugh P, Wang L, Netto EM, Luz E, Harrington WJ, Dezube BJ, Damania B, Dittmer DP (2009) Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. PLoS Pathog 5: e1000389","journal-title":"PLoS Pathog"},{"key":"BFbjc2011275_CR38","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1046\/j.0022-202x.2001.01465.x","volume":"117","author":"C Pellet","year":"2001","unstructured":"Pellet C, Chevret S, Blum L, Gauville C, Hurault M, Blanchard G, Agbalika F, Lascoux C, Ponscarme D, Morel P, Calvo F, Lebbe C (2001) Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 117: 858\u2013863","journal-title":"J Invest Dermatol"},{"key":"BFbjc2011275_CR39","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1097\/00002030-200006160-00034","volume":"14","author":"MD Perloff","year":"2000","unstructured":"Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ (2000) Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 14: 1287\u20131289","journal-title":"AIDS"},{"key":"BFbjc2011275_CR40","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/0140-6736(93)91147-E","volume":"341","author":"CA Presant","year":"1993","unstructured":"Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J, Presant J (1993) Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 341: 1242\u20131243","journal-title":"Lancet"},{"key":"BFbjc2011275_CR41","doi-asserted-by":"publisher","first-page":"e8621","DOI":"10.1371\/journal.pone.0008621","volume":"5","author":"AJ Sasco","year":"2010","unstructured":"Sasco AJ, Jaquet A, Boidin E, Ekouevi DK, Thouillot F, Lemabec T, Forstin MA, Renaudier P, N\u2019Dom P, Malvy D, Dabis F (2010) The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One 5: e8621","journal-title":"PLoS One"},{"key":"BFbjc2011275_CR42","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/jnci\/81.22.1755","volume":"81","author":"G Schwartsmann","year":"1989","unstructured":"Schwartsmann G, Cerski CT, Sander E, Sprinz E, Kronfeld M (1989) P-glycoprotein expression and AIDS-related Kaposi's sarcoma. J Natl Cancer Inst 81: 1755\u20131756","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2011275_CR43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nm0302-225","volume":"8","author":"C Sgadari","year":"2002","unstructured":"Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B (2002) HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8: 225\u2013232","journal-title":"Nat Med"},{"key":"BFbjc2011275_CR44","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1128\/AAC.42.12.3157","volume":"42","author":"RV Srinivas","year":"1998","unstructured":"Srinivas RV, Middlemas D, Flynn P, Fridland A (1998) Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 42: 3157\u20133162","journal-title":"Antimicrob Agents Chemother"},{"key":"BFbjc2011275_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2165\/00063030-200923020-00001","volume":"23","author":"RJ Sullivan","year":"2009","unstructured":"Sullivan RJ, Pantanowitz L, Dezube BJ (2009) Targeted therapy for Kaposi sarcoma. BioDrugs 23: 69\u201375","journal-title":"BioDrugs"},{"key":"BFbjc2011275_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szakacs","year":"2006","unstructured":"Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219\u2013234","journal-title":"Nat Rev Drug Discov"},{"key":"BFbjc2011275_CR47","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/00002030-200305020-00023","volume":"17","author":"D Vishnuvardhan","year":"2003","unstructured":"Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ (2003) Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS 17: 1092\u20131094","journal-title":"AIDS"},{"key":"BFbjc2011275_CR48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489\u2013501","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2011275_CR49","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/jnr.21898","volume":"87","author":"JA Zastre","year":"2009","unstructured":"Zastre JA, Chan GN, Ronaldson PT, Ramaswamy M, Couraud PO, Romero IA, Weksler B, Bendayan M, Bendayan R (2009) Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 87: 1023\u20131036","journal-title":"J Neurosci Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2011275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011275","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T12:56:50Z","timestamp":1741438610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2011275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["BFbjc2011275"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2011.275","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}